Scynexis to Present at Two Key Investor Conferences in September
Event summary
- Scynexis will participate in the 12th Cantor Global Healthcare Conference on September 11, 2026, with a fireside chat at 9:45 a.m. ET.
- The company will also hold 1x1 investor meetings at the H.C. Wainwright 28th Annual Global Investment Conference from September 14-16, 2026.
- SCY-770, a treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD), has been granted Orphan Drug designation.
- Scynexis's antifungal platform includes BREXAFEMME® (ibrexafungerp tablets), licensed to GSK, and SCY-247, currently in clinical development.
The big picture
Scynexis's participation in high-profile investor conferences underscores its focus on engaging with the financial community amid a critical phase of clinical development. The company's pipeline, particularly SCY-770 and its antifungal platform, positions it within the competitive landscape of rare disease and antifungal treatments. Success in these areas could drive significant valuation changes, especially as it leverages partnerships like GSK for commercialization.
What we're watching
- Clinical Progress
- The pace at which SCY-770 advances through clinical trials will determine its market potential in treating ADPKD.
- Partnership Dynamics
- How GSK's commercialization of BREXAFEMME will impact Scynexis's revenue and strategic positioning.
- Investor Sentiment
- Whether the upcoming investor conferences will shift market perception of Scynexis's pipeline and financial prospects.
Related topics